| Ticker<\/th>\n | Security<\/th>\n | Last<\/th>\n | Change<\/th>\n | Change %<\/th>\n<\/tr>\n<\/thead>\n | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ<\/td>\n | JOHNSON & JOHNSON<\/td>\n | 170.42<\/td>\n | +4.55<\/td>\n | +2.74%<\/td>\n<\/tr>\n | ||||||||||||||||||||||
| Powered by<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n The pharmaceutical giant has been developing and testing Janssen’s experimental COVID-19 vaccine candidate, which is in Phase 3 of its clinical trials, in an effort to help eradicate the pandemic that has already infected more than 99 million people worldwide.<\/p>\n "We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon," Gorsky said in the company's fourth-quarter and full-year earnings report.<\/p>\n Although Gorsky stopped short of revealing exactly when the results will be released, he expressed extreme confidence in J&J's ability to "deliver lasting value and continued innovation in 2021 and for years to come."<\/p>\n Johnson & Johnson CEO Alex Gorsky (Illustration by Ulrich Baumgarten via Getty Images)<\/span><\/p>\n JOHNSON & JOHNSON'S COVID-19 CANDIDATE ENTERS THIRD TRIAL PHASE<\/strong><\/p>\n During the fourth quarter, the world’s biggest maker of health care products reported an income of $1.74 billion and a revenue of $22.48 billion, topping Wall Street expectations. Four analysts surveyed by Zacks expected $21.62 billion.<\/p>\n The company had a profit of 65 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.86 per share, which also surpassed Street forecasts. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $1.81 per share.<\/p>\n GET FOX BUSINESS ON THE GO BY CLICKING HERE<\/strong> <\/strong><\/p>\n In September, Johnson & Johnson became the fourth company to enter the final stage of testing its coronavirus candidate in the United States after Moderna, Pfizer-BioNTech and AstraZeneca.<\/p>\n The company has already entered into an agreement with the U.S. government – valued at more than $1 billion — to deliver develop and deliver 100 million doses of its potential vaccine.<\/p>\n The company aims to supply more than one billion doses globally through the course of 2021 as long as the vaccine is safe and effective.<\/p>\n |
![](\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2021\/01\/931\/523\/johnson-and-johnson-vaccine-Alex-Gorsky-.jpg?ve=1&tl=1\")
<\/picture>\n